Mayne And Mithra Add Further US NuvaRing Rival
Third Generic Launch Challenges Amneal And Teva Versions As Well As Prasco AG
Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.
You may also be interested in...
Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
Mayne Agrees Deal For TherapeuticsMD’s US Women’s Health Portfolio
Mayne Pharma enters an exclusive US license agreement with TherapeuticsMD for the latter’s women’s health portfolio. Whether the deal will boost their precarious finances is an open question.
Mayne Banks On Nextstellis As Generics Business Suffers
Mayne Pharma has expressed confidence after its recent US launch of Nextstellis (estetrol/drospirenone) 14.2mg/3mg oral contraceptive tablets. While the firm’s overall sales dipped by 6% in its financial first half, Mayne expects its recent and near-term launches, particularly key dermatology products, to help reverse the trend.